[Immunomodulation in dystrophic diseases of the joints].
Delevskiĭ. Iu P IuP; Isaeva. E G EG
Key Findings
- Joint disease patients showed strong immune abnormalities like T‑cell and B‑cell dysfunction and auto‑immunity
- Thymalin was mentioned alongside other immunomodulators (levamisole, T‑activin, sodium nucleinate) as a potential treatment
- Antibody levels to a cartilage antigen dropped when patients received a drug (arteparon), hinting at an immune‑modulating effect
Practical Outcomes
- For biohackers, the take‑away is that thymalin might help with immune regulation in severe joint disease, but there’s no practical protocol, dosage, or evidence of benefit for healthy individuals or longevity. It’s not a ready‑to‑use supplement for performance or metabolic health.
Summary
The study looked at 357 people with joint problems and found many immune system issues, suggesting they might need drugs that adjust immunity. Thymalin was listed as one of several possible agents, but the paper doesn’t give clear dosing or direct benefits for healthy people or performance goals.
Abstract
Immunological examinations of 357 patients with mixed arthritis, coxarthrosis and aseptic necrosis of the femoral head have revealed substantial immunopathological deviations requiring immunomodulation and influencing surgical outcomes, with inhibition or dysfunction of T and B cellular reactions, inversion of the regulatory index, remarkable autoimmune component, and bacterial sensitization in a considerable part of the examined. In addition to the conventional immunomodulating agents (levamisole, thymalin, T-activin, sodium nucleinate), it is recommended that hemodes and polyglucin may be used, provided they are chosen individually in vitro. The use of ELISA made it possible to reveal a direct strong correlation between the level of antibodies to glycolipid cartilaginous antigen and arteparon as well as a decrease of the number of antibodies in therapeutic administration of the drug. This suggests the immunological mechanisms of the action of arteparon, namely according to the principle of hapten inhibition.
Study Information
pubmed
1992